GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » FCF Margin %

HeartBeam (HeartBeam) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HeartBeam FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HeartBeam's Free Cash Flow for the three months ended in Dec. 2023 was $-2.86 Mil. HeartBeam's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, HeartBeam's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, HeartBeam's current FCF Yield % is -22.14%.

The historical rank and industry rank for HeartBeam's FCF Margin % or its related term are showing as below:


BEAT's FCF Margin % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.36
* Ranked among companies with meaningful FCF Margin % only.


HeartBeam FCF Margin % Historical Data

The historical data trend for HeartBeam's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartBeam FCF Margin % Chart

HeartBeam Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
- - - - -

HeartBeam Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HeartBeam's FCF Margin %

For the Health Information Services subindustry, HeartBeam's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeartBeam's FCF Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, HeartBeam's FCF Margin % distribution charts can be found below:

* The bar in red indicates where HeartBeam's FCF Margin % falls into.



HeartBeam FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

HeartBeam's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-12.349/0
= %

HeartBeam's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.858/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartBeam FCF Margin % Related Terms

Thank you for viewing the detailed overview of HeartBeam's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartBeam (HeartBeam) Business Description

Traded in Other Exchanges
N/A
Address
2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050
HeartBeam Inc is a medical technology company primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. Its initial focus is providing diagnostic data to help physicians with the care management of patients with cardiovascular disease.
Executives
Urioste George De director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen officer: Chief Technology Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno officer: President 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein officer: Chief Financial Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel officer: Chief Operating Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard M Ferrari director, officer: Exec Chm of the BOD 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic 10 percent owner, officer: Chief Executive Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink director 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt officer: Chief Business Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050